217 related articles for article (PubMed ID: 11126152)
1. Clinical characteristic of parenteral iron supplementation in hemodialysis patients receiving erythropoietin therapy.
Kao HH; Chen KS; Tsai CJ; Lee CC; Chang HY
Chang Gung Med J; 2000 Oct; 23(10):608-13. PubMed ID: 11126152
[TBL] [Abstract][Full Text] [Related]
2. The effect of i.v. iron alone or in combination with low-dose erythropoietin in the rapid correction of anemia of chronic renal failure in the predialysis period.
Silverberg DS; Blum M; Agbaria Z; Deutsch V; Irony M; Schwartz D; Baruch R; Yachnin T; Steinbruch S; Iaina A
Clin Nephrol; 2001 Mar; 55(3):212-9. PubMed ID: 11316241
[TBL] [Abstract][Full Text] [Related]
3. Intravenous ferric saccharate as an iron supplement in dialysis patients.
Silverberg DS; Blum M; Peer G; Kaplan E; Iaina A
Nephron; 1996; 72(3):413-7. PubMed ID: 8852489
[TBL] [Abstract][Full Text] [Related]
4. Regular low-dose intravenous iron therapy improves response to erythropoietin in haemodialysis patients.
Taylor JE; Peat N; Porter C; Morgan AG
Nephrol Dial Transplant; 1996 Jun; 11(6):1079-83. PubMed ID: 8671972
[TBL] [Abstract][Full Text] [Related]
5. [Iron replacement in hemodialysis patients with a normal serum ferritin level].
Riedel MK; Morgenstern T
Dtsch Med Wochenschr; 2004 Sep; 129(36):1849-53. PubMed ID: 15368155
[TBL] [Abstract][Full Text] [Related]
6. The efficiency of fractionated parenteral iron treatment in CAPD patients.
Akcicek F; Ozkahya M; Cirit M; Ok E; Unsal A; Toz H; Celik A; Atabay G; Basci A
Adv Perit Dial; 1997; 13():109-12. PubMed ID: 9360661
[TBL] [Abstract][Full Text] [Related]
7. [Intravenous iron sucrose in maintenance dialysis patients with renal anemia: a clinical study].
Li H; Wang SX
Zhonghua Yi Xue Za Zhi; 2009 Feb; 89(7):457-62. PubMed ID: 19567093
[TBL] [Abstract][Full Text] [Related]
8. Effect of intravenous iron supplementation on erythropoiesis in erythropoietin-treated premature infants.
Pollak A; Hayde M; Hayn M; Herkner K; Lombard KA; Lubec G; Weninger M; Widness JA
Pediatrics; 2001 Jan; 107(1):78-85. PubMed ID: 11134438
[TBL] [Abstract][Full Text] [Related]
9. Intravenous iron supplementation for the treatment of the anemia of moderate to severe chronic renal failure patients not receiving dialysis.
Silverberg DS; Iaina A; Peer G; Kaplan E; Levi BA; Frank N; Steinbruch S; Blum M
Am J Kidney Dis; 1996 Feb; 27(2):234-8. PubMed ID: 8659499
[TBL] [Abstract][Full Text] [Related]
10. Low-dose intravenous iron administration in chronic hemodialysis patients treated with recombinant human erythropoietin.
Harmankaya O; Eran A
Ren Fail; 2002 Mar; 24(2):245-7. PubMed ID: 12071600
[TBL] [Abstract][Full Text] [Related]
11. Intravenous ascorbic acid as an adjuvant therapy for recombinant erythropoietin in hemodialysis patients with hyperferritinemia.
Tarng DC; Wei YH; Huang TP; Kuo BI; Yang WC
Kidney Int; 1999 Jun; 55(6):2477-86. PubMed ID: 10354297
[TBL] [Abstract][Full Text] [Related]
12. Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia.
Li H; Wang SX
Blood Purif; 2008; 26(2):151-6. PubMed ID: 18212498
[TBL] [Abstract][Full Text] [Related]
13. Reduction in erythropoietin doses by the use of chronic intravenous iron supplementation in iron-replete hemodialysis patients.
Chang CH; Chang CC; Chiang SS
Clin Nephrol; 2002 Feb; 57(2):136-41. PubMed ID: 11863124
[TBL] [Abstract][Full Text] [Related]
14. Improved response to erythropoietin in peritoneal dialysis patients as compared to hemodialysis patients: role of iron deficiency.
Raja R; Bloom E; Johnson R; Goldstein M
Adv Perit Dial; 1994; 10():135-8. PubMed ID: 7999811
[TBL] [Abstract][Full Text] [Related]
15. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation.
Fishbane S; Frei GL; Maesaka J
Am J Kidney Dis; 1995 Jul; 26(1):41-6. PubMed ID: 7611266
[TBL] [Abstract][Full Text] [Related]
16. Weekly low-dose treatment with intravenous iron sucrose maintains iron status and decreases epoetin requirement in iron-replete haemodialysis patients.
Schiesser D; Binet I; Tsinalis D; Dickenmann M; Keusch G; Schmidli M; Ambühl PM; Lüthi L; Wüthrich RP
Nephrol Dial Transplant; 2006 Oct; 21(10):2841-5. PubMed ID: 16891647
[TBL] [Abstract][Full Text] [Related]
17. Clinical efficacy of recombinant human erythropoietin in the treatment of anemia in hemodialysis patients: influence of dosing regimen, iron status, and serum aluminum.
Tsai JC; Lai YH; Tsai ZY; Chien LJ; Tsai JH
Gaoxiong Yi Xue Ke Xue Za Zhi; 1991 Mar; 7(3):126-35. PubMed ID: 1865507
[TBL] [Abstract][Full Text] [Related]
18. Comparative response to single or divided doses of parenteral iron for functional iron deficiency in hemodialysis patients receiving erythropoietin (EPO).
Saltissi D; Sauvage D; Westhuyzen J
Clin Nephrol; 1998 Jan; 49(1):45-8. PubMed ID: 9491286
[TBL] [Abstract][Full Text] [Related]
19. Sensitivity and specificity of transferrin saturation and serum ferritin as markers of iron status after intravenous iron dextran in hemodialysis patients.
Low CL; Bailie GR; Eisele G
Ren Fail; 1997 Nov; 19(6):781-8. PubMed ID: 9415935
[TBL] [Abstract][Full Text] [Related]
20. Functional iron deficiency in hemodialysis patients with high ferritin.
Kopelman RC; Smith L; Peoples L; Biesecker R; Rizkala AR
Hemodial Int; 2007 Apr; 11(2):238-46. PubMed ID: 17403177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
